United States
# |
Name |
EBITDA Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
95,478.43%
|
Sept. 30, 2024 | USD 12.74 | -6.60% |
|
United States |
|
2 |
68,350.00%
|
Sept. 30, 2024 | USD 14.86 | 5.02% |
|
United States |
|
3 |
1,572.55%
|
March 31, 2024 | USD 2.36 | NA |
|
United States |
|
4 |
504.24%
|
June 30, 2024 | USD 20.26 | -0.64% |
|
United States |
|
5 |
454.78%
|
Sept. 30, 2024 | USD 14.33 | 4.75% |
|
United States |
|
6 |
336.52%
|
Sept. 30, 2024 | USD 6.48 | 0.78% |
|
United States |
|
7 |
330.65%
|
June 30, 2024 | USD 23.28 | 0.82% |
|
United States |
|
8 |
279.15%
|
Dec. 31, 2023 | USD 18.95 | 0.22% |
|
United States |
|
9 |
198.02%
|
Sept. 30, 2024 | USD 4.54 | -7.91% |
|
United States |
|
10 |
172.60%
|
Sept. 30, 2024 | USD 27.49 | 3.85% |
|
United States |
|
11 |
139.81%
|
June 30, 2024 | USD 5.75 | -0.35% |
|
United States |
|
12 |
137.70%
|
Sept. 30, 2024 | USD 26.74 | 0.98% |
|
United States |
|
13 |
112.46%
|
Sept. 30, 2024 | USD 9.24 | 1.32% |
|
United States |
|
14 |
112.20%
|
Sept. 30, 2024 | USD 182.64 | -0.34% |
|
United States |
|
15 |
106.59%
|
Sept. 30, 2024 | USD 15.16 | -0.78% |
|
United States |
|
16 |
102.14%
|
Sept. 30, 2024 | USD 518.30 | 0.08% |
|
United States |
|
17 |
97.60%
|
Sept. 30, 2024 | USD 15.48 | 1.11% |
|
United States |
|
18 |
97.50%
|
Sept. 30, 2024 | USD 41.17 | 0.93% |
|
United States |
|
19 |
96.56%
|
Sept. 30, 2024 | USD 28.97 | 0.83% |
|
United States |
|
20 |
96.45%
|
Sept. 30, 2024 | USD 22.04 | 1.47% |
|
United States |
|
21 |
95.09%
|
Sept. 30, 2024 | USD 31.00 | 0.52% |
|
United States |
|
22 |
94.79%
|
Sept. 30, 2024 | USD 6.28 | 2.28% |
|
United States |
|
23 |
94.74%
|
Sept. 30, 2024 | USD 30.03 | 0.13% |
|
United States |
|
24 |
94.47%
|
June 30, 2024 | USD 10.99 | 2.61% |
|
United States |
|
25 |
94.05%
|
Sept. 30, 2024 | USD 30.34 | 0.76% |
|
United States |
|
26 |
93.63%
|
Sept. 30, 2024 | USD 39.22 | 1.63% |
|
United States |
|
27 |
92.41%
|
Sept. 30, 2024 | USD 14.00 | 2.64% |
|
United States |
|
28 |
91.88%
|
Sept. 30, 2024 | USD 46.91 | 1.06% |
|
United States |
|
29 |
91.53%
|
Sept. 30, 2024 | USD 107.33 | 0.31% |
|
United States |
|
30 |
91.09%
|
Sept. 30, 2024 | USD 108.32 | 2.92% |
|
United States |
|
31 |
90.03%
|
Sept. 30, 2024 | USD 9.62 | 1.16% |
|
United States |
|
32 |
89.81%
|
Sept. 30, 2024 | USD 53.15 | 1.30% |
|
United States |
|
33 |
88.00%
|
Sept. 30, 2024 | USD 54.23 | 1.36% |
|
United States |
|
34 |
87.47%
|
Sept. 30, 2024 | USD 23.70 | 2.24% |
|
United States |
|
35 |
87.29%
|
Sept. 30, 2024 | USD 37.36 | 0.51% |
|
United States |
|
36 |
86.75%
|
Sept. 30, 2024 | USD 5.50 | 2.42% |
|
United States |
|
37 |
86.59%
|
Sept. 30, 2024 | USD 46.13 | 2.26% |
|
United States |
|
38 |
86.29%
|
Sept. 30, 2024 | USD 26.58 | 0.64% |
|
United States |
|
39 |
84.84%
|
Sept. 30, 2024 | USD 33.70 | -0.03% |
|
United States |
|
40 |
83.23%
|
Sept. 30, 2024 | USD 70.65 | 1.62% |
|
United States |
|
41 |
83.07%
|
Sept. 30, 2024 | USD 14.58 | 0.21% |
|
United States |
|
42 |
82.93%
|
Sept. 30, 2024 | USD 19.27 | 2.23% |
|
United States |
|
43 |
82.83%
|
Sept. 30, 2024 | USD 16.54 | 1.22% |
|
United States |
|
44 |
82.18%
|
Sept. 30, 2024 | USD 15.25 | 1.46% |
|
United States |
|
45 |
81.62%
|
Sept. 30, 2024 | USD 13.41 | 3.31% |
|
United States |
|
46 |
81.55%
|
Sept. 30, 2024 | USD 6.26 | -0.48% |
|
United States |
|
47 |
81.23%
|
Sept. 30, 2024 | USD 11.19 | 1.27% |
|
United States |
|
48 |
81.14%
|
Sept. 30, 2024 | USD 35.84 | 1.96% |
|
United States |
|
49 |
80.42%
|
June 30, 2024 | USD 8.04 | NA |
|
United States |
|
50 |
79.81%
|
Sept. 30, 2024 | USD 1.33 K | 2.13% |
|
United States |
The company in United States with the highest EBITDA Margin is Inhibrx Biosciences, Inc. (NasdaqGS: INBX) at 95,478.43%.
The company in United States with the lowest EBITDA Margin is Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) at -2,003,766,400.00%.
The top 10 companies in United States by EBITDA Margin are Inhibrx Biosciences, Inc., Gatos Silver, Inc., Oramed Pharmaceuticals Inc., Adams Diversified Equity Fund, Inc., Kingstone Companies, Inc., Ellington Residential Mortgage REIT, Adams Natural Resources Fund, Inc., NB Private Equity Partners Limited, Maravai LifeSciences Holdings, Inc. and Hannon Armstrong Sustainable Infrastructure Capital, Inc..
The bottom 10 companies in United States by EBITDA Margin are Inhibikase Therapeutics, Inc., Heart Test Laboratories, Inc., DatChat, Inc., Allogene Therapeutics, Inc., Forte Biosciences, Inc., Immix Biopharma, Inc., Bullfrog AI Holdings, Inc. Common Stock, Benitec Biopharma Inc., Mullen Automotive, Inc. and Cadrenal Therapeutics, Inc. Common Stock.